Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Accured Expenses: 2009-2017

Historic Change in Accured Expenses for Ani Pharmaceuticals (ANIP) over the last 9 years, with Dec 2017 value amounting to $644,000.

  • Ani Pharmaceuticals' Change in Accured Expenses fell 43.14% to $1.0 million in Q3 2018 from the same period last year, while for Sep 2018 it was $174,000, marking a year-over-year increase of 74.00%. This contributed to the annual value of $644,000 for FY2017, which is 31.49% down from last year.
  • Ani Pharmaceuticals' Change in Accured Expenses amounted to $644,000 in FY2017, which was down 31.49% from $940,000 recorded in FY2016.
  • Ani Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $940,000 during FY2016, with a 5-year trough of -$67,000 in FY2013.
  • Moreover, its 3-year median value for Change in Accured Expenses was $644,000 (2017), whereas its average is $558,000.
  • In the last 5 years, Ani Pharmaceuticals' Change in Accured Expenses tumbled by 132.68% in 2013 and then surged by 944.44% in 2016.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Accured Expenses (Yearly) stood at -$67,000 in 2013, then soared by 458.21% to $240,000 in 2014, then slumped by 62.50% to $90,000 in 2015, then soared by 944.44% to $940,000 in 2016, then slumped by 31.49% to $644,000 in 2017.